On the immunotropic effects of a new combined pharmaconutraceutical preparation in osteoarthritis
Osteoarthritis (OA) is one of the leading causes of disability in the world, but the efficacy and safety of its treatment remain extremely low. This review presents epidemiology of OA, mechanism of its development and modern possibilities of pharmacological regulation of immune-mediated inflammation...
Saved in:
| Main Authors: | I. V. Sarvilina, A. M. Lila, O. A. Gromova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-08-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmaconutraceutical Chondroguard®TRIO – chondroprotector with immunomodulatory activity
by: O. A. Shavlovskaya, et al.
Published: (2023-08-01) -
On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases
by: O. A. Gromova, et al.
Published: (2022-08-01) -
Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views
by: O. A. Shavlovskaya, et al.
Published: (2022-08-01) -
Evidence base of pharmaconutraceuticals with chondroprotective action
by: O. A. Shavlovskaya, et al.
Published: (2024-04-01) -
Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy
by: O. A. Shavlovskaya, et al.
Published: (2023-11-01)